The client for the cell-sorter is Owl biomedical.

"The sorting of human cells is becoming important in the treatment of cancer, development of regenerative medicines and the diagnosis of disease and chemotherapy efficacy," says Dr John Foster, CEO of Owl.

The IP for the cell-sorter ws developed by IMT using knowledge gained from working in optics, 3-D microfluidics and electromagnetic actuation. Once bad cells are isolated it is possible to tailor treatments to repair and heal them.

To read full article, please click here.